Traws Pharma Inc. (TRAW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript
Traws Pharma, Inc. (NASDAQ:TRAW ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant Iain D. Dukes - Interim CEO, Secretary & Director Robert R.
Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript
Traws Pharma, Inc. (NASDAQ:TRAW ) Virtual Investor Event March 31, 2025 10:00 AM ET Company Participants Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza – Chief Science Officer-Virology Iain Dukes – Executive Chairman Bruce Mackle – LifeSci Advisors Conference Call Participants Operator Good morning, and welcome to the Traws Pharma Investor Call on Bird Flu and COVID and Traws Innovative Small Molecule Product Candidates. At this time all attendees are in a listen-only mode.
Traws Pharma stock soars 200% on encouraging bird flu drug data
Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug demonstrated safety and tolerability, and maintained blood levels above the EC90 for more than 23 days in a Phase I clinical trial.
Traws Pharma Inc. (TRAW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Traws Pharma Inc. ever had a stock split?
Traws Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Iain D. Dukes DPHIL, CEO | NASDAQ (CM) Exchange | 68232V884 CUSIP |
| US Country | 6 Employees | - Last Dividend | 23 Sep 2024 Last Split | - IPO Date |
Overview
Traws Pharma, Inc. is a clinical stage biopharmaceutical company with a primary focus on developing oral small molecule product candidates. These candidates are aimed at treating respiratory viral diseases and cancer. Originally operating under the name Onconova Therapeutics, Inc., the company underwent a name change to Traws Pharma, Inc. in April 2024. Since its incorporation in 1998, Traws Pharma has been dedicated to advancing a portfolio of novel therapies designed to tackle treatment resistance in these critical areas. Headquartered in Newtown, Pennsylvania, Traws Pharma leverages its expertise in drug development to combat some of the most challenging diseases facing the medical community today.
Products and Services
- TRX01 (travatrelvir) - An investigational Mpro/3CL inhibitor currently in development for the treatment of COVID-19. This small molecule oral candidate is part of Traws Pharma’s endeavor to address the ongoing challenge of treatment resistance in COVID-19 therapeutics.
- TRX100 (viroxavir) - Another promising candidate in Traws Pharma’s portfolio, viroxavir is an endonuclease inhibitor aimed at treating pandemic influenza. It’s part of the company’s broader strategy to provide novel solutions for respiratory viral diseases beyond the COVID-19 pandemic.
- Narazaciclib - This multi-kinase CDK4/6 inhibitor is currently undergoing Phase 1/2 clinical trials in patients with cancer. The trials are exploring its efficacy both with and without the co-administration of letrozole to establish a recommended phase 2 dose. The focus is on further development for the treatment of endometrial cancer, highlighting Traws Pharma’s commitment to advancing cancer treatment options.
- Oral Rigosertib - Administered alone or in combination with other treatments, oral rigosertib is under investigation for its potential in treating various cancers. Its development underscores the company’s ongoing efforts to expand its cancer therapeutics portfolio with innovative and targeted therapies.
Contact Information
